NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
Sign in Subscribe

Raymond James Starts Coverage on Phathom Pharmaceuticals With Strong Buy

Raymond James initiates coverage on Phathom Pharmaceuticals with a Strong Buy rating and a $28 price target, highlighting Voquezna’s unique FDA-approved profile and strong long-term outlook.

Raymond James Starts Coverage on Phathom Pharmaceuticals With Strong Buy
"Voquezna", Credit: Phathom Pharmaceuticals
Already have an account? Sign in.
12/12/2025 · 6:51 AM
PHAT
/ Don’t stop at just one post.

Related↓

Phathom Responds to Lawsuit Challenging VOQUEZNA’s 10-Year Exclusivity
10/23/2026 · 9:53 AM

Phathom Defends VOQUEZNA Exclusivity as Generic Challenge Reaches Court

BDR Pharmaceuticals has sued the FDA over its decision to extend VOQUEZNA’s new chemical entity exclusivity through May 2032 under the GAIN Act.

/ Subscriber only
/ Read more

Feed↓

NVIDIA Cuts Intel Stake by 25%, Portfolio Falls to $48.3 Billion in Latest 13F
Featured/ 11/16/2026 · 5:46 PM

NVIDIA Cuts Intel Stake by 25%, Portfolio Falls to $48.3 Billion in Latest 13F

NVIDIA’s September 2026 13F reveals a smaller $48.3B portfolio, led by SpaceX after a major reduction in its Intel stake from the prior quarter.

/ Subscriber only
Rosemont Pharmaceuticals to Acquire Aytu BioPharma in $2.70 All-Cash Tender Offer
Featured/ 11/16/2026 · 5:20 PM

Rosemont Pharmaceuticals to Acquire Aytu BioPharma in $2.70 All-Cash Tender Offer

Rosemont aims to expand its U.S. specialty pharma presence.

/ Subscriber only
Kalshi to Launch Stock Trading After Acquiring Broker, Pressuring Robinhood Shares
Featured/ 11/16/2026 · 3:35 PM

Kalshi to Launch Stock Trading After Acquiring Broker, Pressuring Robinhood Shares

Kalshi acquired a New York broker and plans to launch stock and ETF trading within two months, pressuring shares of Robinhood and Bullish.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI